keyword
https://read.qxmd.com/read/38737610/hypofractionated-radiotherapy-for-glioblastoma-a-large-institutional-retrospective-assessment-of-2-approaches
#1
JOURNAL ARTICLE
Thomas H Beckham, Michael K Rooney, Mary F McAleer, Amol J Ghia, Martin C Tom, Subha Perni, Susan McGovern, David Grosshans, Caroline Chung, Chenyang Wang, Brain De, Todd Swanson, Arnold Paulino, Wen Jiang, Sherise Ferguson, Chirag B Patel, Jing Li, Debra N Yeboa
BACKGROUND: Glioblastoma (GBM) poses therapeutic challenges due to its aggressive nature, particularly for patients with poor functional status and/or advanced disease. Hypofractionated radiotherapy (RT) regimens have demonstrated comparable disease outcomes for this population while allowing treatment to be completed more quickly. Here, we report our institutional outcomes of patients treated with 2 hypofractionated RT regimens: 40 Gy/15fx (3w-RT) and 50 Gy/20fx (4w-RT). METHODS: A single-institution retrospective analysis was conducted of 127 GBM patients who underwent 3w-RT or 4w-RT...
June 2024: Neuro-oncology Practice
https://read.qxmd.com/read/38733402/the-efficacy-and-safety-of-adding-pd-1-blockade-to-induction-chemotherapy-and-concurrent-chemoradiotherapy-ic-ccrt-for-locoregionally-advanced-nasopharyngeal-carcinoma-an-observational-propensity-score-matched-analysis
#2
JOURNAL ARTICLE
Ya-Nan Jin, Meng-Yun Qiang, Ying Wang, Yu-Jing Lin, Ren-Wei Jiang, Wan-Wei Cao, Wang-Jian Zhang, Si-Yang Wang, Hong-Yu Zhang, Ji-Jin Yao
BACKGROUND: Despite the success of PD-1 blockade in recurrent/metastatic nasopharyngeal carcinoma (NPC), its effect for locoregionally advanced NPC (LANPC) remains unclear. This study aimed to evaluate the benefit of adding PD-1 blockade to the current standard treatment (gemcitabine and cisplatin IC <induction chemotherapy> plus cisplatin CCRT <concurrent chemoradiotherapy>) for LANPC patients. METHODS: From January 2020 to November 2022, 347 patients with non-metastatic high-risk LANPC (stage III-IVA, excluding T3-4N0) were included...
May 11, 2024: Cancer Immunology, Immunotherapy: CII
https://read.qxmd.com/read/38732321/impressive-response-to-tandem-peptide-receptor-radionuclide-therapy-with-177-lu-225-acdota-lm3-somatostatin-receptor-antagonist-in-a-patient-with-therapy-refractory-rapidly-progressive-neuroendocrine-neoplasm-of-the-pancreas
#3
JOURNAL ARTICLE
Elisabetta Perrone, Kriti Ghai, Aleksandr Eismant, Mikkel Andreassen, Seppo W Langer, Ulrich Knigge, Andreas Kjaer, Richard P Baum
The present report describes the history of a 58-year-old woman with a rapidly progressing neuroendocrine pancreatic tumor (initially G2) presenting with extensive liver, bone, and lymph node metastases. Previous treatments included chemotherapy, hemithyroidectomy for right lobe metastasis, Peptide Receptor Radionuclide Therapy (PRRT) with [177 Lu]Lu-DOTATATE, Lanreotide, Everolimus, and liver embolization. Due to severe disease progression, after a liver biopsy revealing tumor grade G3, PRRT with the somatostatin receptor antagonist LM3 was initiated...
April 26, 2024: Diagnostics
https://read.qxmd.com/read/38731418/unraveling-the-nephroprotective-potential-of-papaverine-against-cisplatin-toxicity-through-mitigating-oxidative-stress-and-inflammation-insights-from-in-silico-in-vitro-and-in-vivo-investigations
#4
JOURNAL ARTICLE
Shimaa A Abass, Abdullah A Elgazar, Sanad S El-Kholy, Amal I El-Refaiy, Reem A Nawaya, Mashooq Ahmad Bhat, Foad A Farrag, Abdelrahman Hamdi, Marwa Balaha, Mohammed A El-Magd
Cisplatin is a potent compound in anti-tumor chemotherapy; however, its clinical utility is hampered by dose-limiting nephrotoxicity. This study investigated whether papaverine could mitigate cisplatin-induced kidney damage while preserving its chemotherapeutic efficacy. Integrative bioinformatics analysis predicted papaverine modulation of the mechanistic pathways related to cisplatin renal toxicity; notably, mitogen-activated protein kinase 1 (MAPK1) signaling. We validated protective effects in normal kidney cells without interfering with cisplatin cytotoxicity on a cancer cell line...
April 23, 2024: Molecules: a Journal of Synthetic Chemistry and Natural Product Chemistry
https://read.qxmd.com/read/38731040/optimizing-surgical-management-for-rhegmatogenous-retinal-detachment-in-eyes-with-active-retinoblastoma-a-safety-driven-approach
#5
JOURNAL ARTICLE
Yacoub A Yousef, Omar AlHabahbeh, Mona Mohammad, Hadeel Halalsheh, Mustafa Mehyar, Mario Damiano Toro, Ibrahim AlNawaiseh
Introduction: Intraocular surgeries are conventionally contraindicated for patients with active retinoblastoma (Rb) due to the potential risk of tumor dissemination. However, surgery is occasionally necessary to preserve vision in patients with a single eye when the eye is complicated by rhegmatogenous retinal detachment (RRD). Objective: This study aims to evaluate the outcomes of surgical repair for RRD in pediatric patients with active Rb utilizing a non-drainage scleral buckling approach. Results: This cohort included six eyes from six patients who harbored active Rb and presented with RRD; one had a concurrent tractional component...
April 25, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38730129/secondary-ileal-lymph-node-metastases-from-rectal-cancer-a-case-report
#6
JOURNAL ARTICLE
Makoto Ando, Nobuyuki Takemura, Ryo Oikawa, Yuhi Yoshizaki, Fuyuki Inagaki, Fuminori Mihara, Tomomichi Kiyomatsu, Kazuhiko Yamada, Norihiro Kokudo
BACKGROUND: Colorectal cancer can invade adjacent organs, but rarely metastasizes to the regional lymph nodes (LNs) of the invaded organ. Herein, we report a case of rectal cancer invading the ileum and metastasized to the regional ileal LNs. CASE PRESENTATION: A 77-year-old male presented abdominal pain and anorexia, diagnosed with rectal cancer invading the small intestine and concurrently metastasized to the regional LN of the intestine and liver. High anterior resection and partial resection of the small intestine was performed, then, the patient was referred to our hospital for chemotherapy...
May 11, 2024: Surgical Case Reports
https://read.qxmd.com/read/38729039/prospective-comparison-of-acute-severe-toxicities-between-smokers-and-non-smokers-during-radiotherapy-for-head-and-neck-cancers
#7
JOURNAL ARTICLE
C Invernizzi, A Da Silva Ribeiro Mota, C Barbe, L Bouazzi, O Marques, L Munschi, C Marchand-Crety, N Jacquin, X Dubernard, A Beddok, C Lasset, N Assouly, S Vignot, E Brenet
BACKGROUND AND PURPOSE: The association between smoking and acute radiation toxicities of head and neck cancer (HNC) is currently unproven. The aim of the study was to compare the occurrence of acute severe toxicity between active and non-active smokers treated for HNC by radiotherapy. MATERIALS AND METHODS: A prospective monocentric cohort study included patients treated by (chemo)radiotherapy for HNC from January 2021 to January 2023. Smoking status was recorded...
May 9, 2024: Oral Oncology
https://read.qxmd.com/read/38728764/stereotactic-radiosurgery-for-brain-metastasis-from-cholangiocarcinoma
#8
JOURNAL ARTICLE
Ali Haluk Düzkalir, Yavuz Samanci, Cheng-Chia Lee, Huai-Che Yang, Ajay Niranjan, L Dade Lunsford, Zhishuo Wei, Priyanka N Srinivasan, Samantha Dayawansa, Jason P Sheehan, Samir Patel, David Mathieu, Brad E Zacharia, Brandon Santhumayor, Douglas Kondziolka, Selcuk Peker
OBJECTIVE: Accounting for approximately 15% of primary liver cancers and 3% of gastrointestinal malignancies, cholangiocarcinoma (CCA) poses a serious health concern given its high mortality rate. Managing brain metastases (BMs) from CCA is challenging because of their rarity and poor prognosis, with little guidance on treatment from the literature. In this study, the authors aimed to evaluate the safety and efficacy of stereotactic radiosurgery (SRS) in managing BMs from CCA. METHODS: This multicenter retrospective study included 13 CCA patients with 41 BMs treated with SRS from October 2006 to April 2022 at eight institutions affiliated with the International Radiosurgery Research Foundation...
May 10, 2024: Journal of Neurosurgery
https://read.qxmd.com/read/38728434/distraction-osteogenesis-reconstruction-following-resection-of-bone-sarcomas-surgical-functional-and-oncological-outcomes-from-a-prospective-trial-analysis
#9
JOURNAL ARTICLE
Anthony Bozzo, Varun Aysola, Caleb M Yeung, John H Healey, Daniel E Prince
BACKGROUND: While sustainable long-term function has been established for biological reconstruction with distraction osteogenesis (DO) following osseous resections, there is a paucity of published data informing surgeons and patients on important milestones in the reconstructive process. The objectives of this study were to determine when to expect complete bone healing and full weight-bearing as well as to quantify the influence of chemotherapy on the osseous regeneration process. METHODS: Prospectively, pathological and clinical data were collected for 30 consecutive patients who underwent primary or secondary DO-based reconstruction following osseous resection from 2018 to 2021...
May 10, 2024: Journal of Bone and Joint Surgery. American Volume
https://read.qxmd.com/read/38726470/safety-and-oncological-outcome-of-early-intraoperative-intravesicle-mitomycin-c-vs-deferred-instillation-in-patients-receiving-robot-assisted-radical-nephroureterectomy
#10
JOURNAL ARTICLE
Sheng-Feng Chou, Wei-Ching Lin, Han Chang, Chi-Ping Huang
INTRODUCTION: Radical nephroureterectomy with concurrent bladder cuff excision (RNUBCE) is the gold standard surgical approach for high-risk primary upper tract urothelial carcinoma (UTUC). Given the notably high incidence of bladder tumor recurrence following this procedure, this study aimed to evaluate the effect and safety of intraoperative mitomycin-C (MMC) instillation vs. deferred instillation on overall oncological outcomes following robot-assisted RNUBCE. METHODS: This is a retrospective chart review study...
2024: Frontiers in Surgery
https://read.qxmd.com/read/38725620/prognostic-analysis-of-stage-iiic1p-cervical-cancer-patients
#11
JOURNAL ARTICLE
Ting Gao, Zixuan Yang, Liqun Wei, Xiaobi Tang, Shanshan Ma, Li Jiang, Yong Zhang, Fang Wu
BACKGROUND: Stage IIIC1p cervical cancer is characterized by marked heterogeneity and considerable variability in the postoperative prognosis. This study aimed to identify the clinical and pathological characteristics affecting the survival of patients diagnosed with stage IIIC1p cervical cancer. METHODS: We retrospectively analyzed patients diagnosed with stage IIIC1p cervical cancer who underwent radical hysterectomy and lymph node dissection between March 2012 and March 2022...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38725619/treatment-with-chemo-radiation-in-old-patients-%C3%A2-76-years-of-age-with-newly-diagnosed-non-metastatic-squamous-cell-cancer-of-the-head-and-neck-region-real-world-data-from-a-tertiary-referral-center
#12
JOURNAL ARTICLE
Leah-Sophie Winkler, Marlen Haderlein, Sabine Semrau, Florian Putz, Daniel Höfler, Sarina K Müller, Heinrich Iro, Marco Kesting, Rainer Fietkau, Philipp Schubert
PURPOSE: Treatment of patients with cancer of the head and neck region is in focus in a multitude of studies. Of these patients, one patient group, those aged 76 and more, is mostly underrepresented despite requiring thorough and well-reasoned treatment decisions to offer curative treatment. This study investigates real-world data on curative treatment of old (≥76 years) patients with newly diagnosed squamous cell carcinoma of the head and neck region (HNSCC). PATIENTS AND METHODS: Between January 2010 and December 2021, we identified 71 patients older than 76 years with newly diagnosed HNSCC and cM0 at the Department of Radiation Oncology of the University Hospital of Erlangen-Nuremberg...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38723775/risk-prediction-model-for-radiation-induced-dermatitis-in-patients-with-cervical-carcinoma-undergoing-chemoradiotherapy
#13
JOURNAL ARTICLE
Hong Yang, Yaru Zhang, Fanxiu Heng, Wen Li, Yumei Feng, Jie Tao, Lijun Wang, Zhili Zhang, Xiaofan Li, Yuhan Lu
PURPOSE: Radiation-induced dermatitis (RD) is a common side effect of therapeutic ionizing radiation that can severely affect patient quality of life. This study aimed to develop a risk prediction model for the occurrence of RD in patients with cervical carcinoma undergoing chemoradiotherapy using electronic medical records (EMRs). METHODS: Using electronic medical records, the clinical data of patients who underwent simultaneous radiotherapy and chemotherapy at a tertiary cancer hospital between 2017 and 2022 were retrospectively collected, and the patients were divided into two groups: a training group and a validation group...
May 7, 2024: Asian Nursing Research
https://read.qxmd.com/read/38720351/carbon-ion-radiotherapy-for-mesonephric-adenocarcinoma-of-the-uterine-cervix-a-case-report
#14
JOURNAL ARTICLE
Nao Kobayashi, Takahiro Oike, Ken Ando, Kazutoshi Murata, Tomoaki Tamaki, Shin-Ei Noda, Kayoko Kogure, Sumihito Nobusawa, Tetsunari Oyama, Tatsuya Ohno
BACKGROUND: Mesonephric adenocarcinoma is an extremely rare subtype of uterine cervical cancer that is associated with a poor prognosis and for which a standardized treatment protocol has not been established. Carbon ion radiotherapy (CIRT) is an emerging radiotherapy modality that has been shown to have a favorable anti-tumor effect, even for tumors resistant to conventional photon radiotherapy or chemotherapy. However, there is no report on CIRT outcomes for mesonephric adenocarcinoma of the uterine cervix...
May 9, 2024: Journal of Medical Case Reports
https://read.qxmd.com/read/38718615/co-delivery-of-plinabulin-and-tirapazamine-boosts-anti-tumor-efficacy-by-simultaneously-destroying-tumor-blood-vessels-and-killing-tumor-cells
#15
JOURNAL ARTICLE
Jianlin Lv, Yajun Xu, Ya Liu, Kazuo Sakurai, Haiyang Yu, Zhaohui Tang
It is imperative to optimize chemotherapy for heightened anti-tumor therapeutic efficacy. Unrestrained tumor cell proliferation and sustained angiogenesis are pivotal for cancer progression. Plinabulin, a vascular disrupting agent, selectively destroys tumor blood vessels. Tirapazamine (TPZ), a hypoxia-activated prodrug, intensifies cytotoxicity in diminishing oxygen levels within tumor cells. Despite completing Phase III clinical trials, both agents exhibited modest treatment efficiency due to dose-limiting toxicity...
April 30, 2024: Biomaterials
https://read.qxmd.com/read/38718318/breaking-ground-in-recurrent-or-metastatic-head-and-neck-squamous-cell-carcinoma-novel-therapies-beyond-pd-l1-immunotherapy
#16
REVIEW
Ari J Rosenberg, Cesar A Perez, Wenji Guo, Jose Monteiro de Oliveira Novaes, Kamilla F Oliveira da Silva Reis, Patrick W McGarrah, Katharine A R Price
The treatment for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) with immune checkpoint inhibitors (anti-PD1) with or without chemotherapy has led to an improvement in survival. Yet, despite this therapeutic advancement, only 15%-19% of patients remain alive at four years, highlighting the poor survival and unmet need for improved therapies for this patient population. Some of the key evolving novel therapeutics beyond anti-PD1 in R/M HNSCC have included therapeutic vaccine therapies, bispecific antibodies/fusion proteins and multitargeted kinase inhibitors, and antibody-drug conjugates (ADCs)...
June 2024: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/38716585/regorafenib-with-immunotherapy-versus-regorafenib-alone-as-second-line-treatment-for-hepatocellular-carcinoma-a-multicenter-real-world-study
#17
MULTICENTER STUDY
Liang Qiao, Wei He, Guoying Wang, Huanwei Chen, Fuxi Huang, Bo Zhang, Yuxiong Qiu, Shaoru Liu, Zhenkun Huang, Yichuan Yuan, Jiliang Qiu, Yunfei Yuan, Binkui Li
INTRODUCTION: Regorafenib remains the standard and widely used second-line strategy for advanced hepatocellular carcinoma (HCC). There is still a lack of large-scale multicenter real-world evidence concerning the concurrent use of regorafenib with immune checkpoint inhibitors (ICI). This study aims to evaluate whether combining regorafenib with ICI provides greater clinical benefit than regorafenib monotherapy as second-line therapy for advanced HCC under real-world circumstances. PATIENTS AND METHODS: The study included 208 patients from five medical facilities...
May 2024: Cancer Medicine
https://read.qxmd.com/read/38716033/preliminary-investigation-of-the-efficacy-and-indications-of-proton-beam-therapy-for-stage-iv-pancreatic-adenocarcinoma
#18
JOURNAL ARTICLE
Hisashi Yamaguchi, Takahiro Kato, Yuki Narita, Michitaka Honda, Koichi Hamada, Yojiro Ishikawa, Ichiro Seto, Yoshiaki Takagawa, Yasuhiro Kikuchi, Masao Murakami
BACKGROUND: The present study aimed to evaluate proton beam therapy (PBT) for stage IV pancreatic adenocarcinoma and its metastases and define the criteria for eligibility. Materials and methods: We retrospectively evaluated the patients who had a histopathological diagnosis of pancreatic adenocarcinoma, had progressed to stage IV, and underwent PBT for both the primary and some metastatic lesions between 2017 and 2022. PBT was performed using the passive scattering technique. RESULTS: Sixteen patients (median age, 72 years; range, 55-85 years) were enrolled...
April 2024: Curēus
https://read.qxmd.com/read/38715493/-the-505th-case-refractory-ascites-and-monoclonal-immunoglobulin
#19
JOURNAL ARTICLE
F J Zhang, W Y Zheng, X Wang, X Y Jiang, J L Zhuang
A 52-year-old woman was admitted with a primary complaint of abdominal distension and increased abdominal circumference for more than half a year. There was no evidence of infection or solid tumor on abdominocentesis or laparoscopic surgery. Concurrently, smoldering multiple myeloma was diagnosed. Due to refractory ascites and portal hypertension, a transjugular intrahepatic portosystemic shunt was performed, but the efficacy was not satisfactory. As the anemia progressed, she was finally diagnosed with active multiple myeloma after monoclonal plasma cells were detected in the ascites by flow cytometry...
May 1, 2024: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://read.qxmd.com/read/38715344/advanced-tumor-electric-fields-therapy-a-review-of-innovative-research-and-development-and-prospect-of-application-in-glioblastoma
#20
REVIEW
Jinxin Lan, Yuyang Liu, Junyi Chen, Hongyu Liu, Yaping Feng, Jialin Liu, Ling Chen
BACKGROUND: Glioblastoma multiforme (GBM) is an aggressive malignant tumor with a high mortality rate and is the most prevalent primary intracranial tumor that remains incurable. The current standard treatment, which involves surgery along with concurrent radiotherapy and chemotherapy, only yields a survival time of 14-16 months. However, the introduction of tumor electric fields therapy (TEFT) has provided a glimmer of hope for patients with newly diagnosed and recurrent GBM, as it has been shown to extend the median survival time to 20 months...
May 2024: CNS Neuroscience & Therapeutics
keyword
keyword
158729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.